In an attempt to find better criteria for the evaluation of prophylactic treatment of asthma, we have studied the significance and the correlations of the 3 parameters usually measured: symptoms, bronchodilator requirements, changes in Peak Expiratory Flow (PEF). We have collected these data daily over a 16 week period in 13 adult asthmatics allergic to Dermatophagoides pteronyssinus. For each patient, the 3 scores were compared graphically. Linear regression was used to analyze the individual relationship between 2 daily scores. Incomplete cards mostly revealed unexpected behaviour (e.g. normal lung function but many symptoms recorded) and cannot of course be taken into account in a trial protocol. We found a good correlation between PEF and symptom scores in 10 out of 13 patients and we could point out the poor correlation between medication score and the other scores. To our knowledge, it is the first time such an objective result has been shown in asthmatic adults. Our analysis provides data which should improve the studies of prophylactic treatment efficacy in asthma.

Download full-text PDF

Source

Publication Analysis

Top Keywords

prophylactic treatment
12
evaluation prophylactic
8
study criteria
4
criteria clinical
4
clinical evaluation
4
treatment bronchial
4
bronchial asthma
4
asthma attempt
4
attempt find
4
find better
4

Similar Publications

Cancer is one of the leading causes of death worldwide. In recent years, immune checkpoint inhibitor therapies, in addition to standard immuno- or chemotherapy and surgical approaches, have massively improved the outcome for cancer patients. However, these therapies have their limitations and improved strategies, including access to reliable cancer vaccines, are needed.

View Article and Find Full Text PDF

Introduction: Antibiotic overuse is driving a global rise in antibiotic resistance, highlighting the need for robust antimicrobial stewardship (AMS) initiatives to improve prescription practices. While antimicrobials are essential for treating sepsis and preventing surgical site infections (SSIs), they can inadvertently disrupt the gut microbiota, leading to postoperative complications. Treatment methods vary widely across nations due to differences in drug choice, dosage, and therapy duration, affecting antibiotic resistance rates, which can reach up to 51% in some countries.

View Article and Find Full Text PDF

Background: More real-world data are needed to complement existing phase III studies on the efficacy and safety of recombinant factor IX Fc fusion protein (rFIXFc) in people with haemophilia B.

Objectives: We report final data from the B-SURE study, evaluating the real-world usage and effectiveness of rFIXFc in France.

Methods: Previously treated patients (all ages/severities) received on-demand or prophylactic rFIXFc during B-SURE.

View Article and Find Full Text PDF

Background: Persistent infection with human papillomavirus (HPV) is associated with most cervical and anal cancer cases and a large fraction of other anogenital and oropharyngeal cancers. The prophylactic HPV vaccines are known to prevent HPV infections and HPV-associated disease, although there is evidence of reduced response to the HPV vaccination among individuals living with HIV. Prior studies among individuals without HIV suggest that a single HPV vaccine dose induces humoral immune responses that, while lower than those induced by two or three doses, still confer protection against HPV infection.

View Article and Find Full Text PDF

Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection.

Antiviral Res

January 2025

CIRI, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS, UMR5308, Univ Lyon, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France.

Nipah virus (NiV) is a lethal zoonotic paramyxovirus that can be transmitted from person to person through the respiratory route. There are currently no licensed vaccines or therapeutics. A lipopeptide-based fusion inhibitor was developed and previously evaluated for efficacy against the NiV-Malaysia strain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!